Diurnal group | Radio Compass News

Diurnal Presents PIII Extension Study Data for Modified-Release Hydrocortisone

15 Jun 2023 //

PR NEWSWIRE

Amid launch efforts, Neurocrine doles out £48M to acquire UK biotech Diurnal

30 Aug 2022 //

FIERCEPHARMA

Diurnal shares rocket after knock-out £48mln bid from US biotech

29 Aug 2022 //

PROACTIVEINVESTORS

EffRx Pharma Signs Exclusive License Agreement With Diurnal

26 Apr 2022 //

BUSINESSWIRE

Efmody distribution and marketing agreement signed with EffRx for Switzerland

25 Apr 2022 //

IPGROUPPLC

First adrenal insufficiency patient dosed in Phase 2 study

10 Feb 2022 //

PHARMATIMES

Diurnal inks pact with ExCEEd Orphan for marketing of Alkindi & Efmodyin

16 Oct 2021 //

PHARMABIZ

Diurnal Group launches Efmody for rare condition congenital adrenal hyperplasia

16 Sep 2021 //

PHARMABIZ

Commercial launch of Efmody in the UK

13 Sep 2021 //

INVESTEGATE

MHRA authorises Diurnal’s CAH therapy Efmody

02 Jul 2021 //

PHARMATIMES

Diurnal Europe`s Efmody (hydrocortisone) Receives Approval in Europe

27 May 2021 //

EMA

Phase III results on Diurnal’s Chronocort published in endocrinology journal

02 Feb 2021 //

PHARMALETTER

Diurnal and Citrine sign licensing agreement for Alkindi

27 Jan 2021 //

PHARMAFILE

Diurnal raising up to £10m in placing and open offer

09 Oct 2020 //

HL

Positive DITEST Regulatory Meeting with US FDA

30 Jul 2020 //